Tenax Therapeutics, Inc. (TENX)
1.94
+0.16
(+8.99%)
USD |
NASDAQ |
Sep 04, 16:00
1.92
-0.02
(-1.03%)
After-Hours: 20:00
Tenax Therapeutics Research and Development Expense (Quarterly) : 12.85M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.85M |
| March 31, 2026 | 11.54M |
| December 31, 2025 | 10.54M |
| September 30, 2025 | 10.33M |
| June 30, 2025 | 6.121M |
| March 31, 2025 | 5.683M |
| December 31, 2024 | 4.594M |
| September 30, 2024 | 3.112M |
| June 30, 2024 | 2.328M |
| March 31, 2024 | 2.676M |
| December 31, 2023 | 1.699M |
| September 30, 2023 | 1.066M |
| June 30, 2023 | 0.1979M |
| March 31, 2023 | 0.2657M |
| December 31, 2022 | 1.135M |
| September 30, 2022 | 1.540M |
| June 30, 2022 | 1.524M |
| March 31, 2022 | 1.178M |
| December 31, 2021 | 0.9156M |
| September 30, 2021 | 1.162M |
| June 30, 2021 | 0.6932M |
| March 31, 2021 | 22.38M |
| December 31, 2020 | 0.891M |
| September 30, 2020 | 1.052M |
| June 30, 2020 | 1.275M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.342M |
| December 31, 2019 | 1.422M |
| September 30, 2019 | 0.917M |
| June 30, 2019 | 0.6493M |
| March 31, 2019 | 0.4828M |
| December 31, 2018 | 0.5069M |
| September 30, 2018 | 0.3626M |
| June 30, 2018 | 0.3112M |
| March 31, 2018 | 0.0586M |
| December 31, 2017 | |
| September 30, 2017 | 0.2535M |
| June 30, 2017 | 1.223M |
| March 31, 2017 | 2.049M |
| December 31, 2016 | 2.528M |
| September 30, 2016 | 3.233M |
| June 30, 2016 | 3.43M |
| July 31, 2015 | 1.743M |
| April 30, 2015 | 1.902M |
| January 31, 2015 | 1.219M |
| October 31, 2014 | 2.548M |
| July 31, 2014 | 0.9579M |
| April 30, 2014 | 0.776M |
| January 31, 2014 | 0.6774M |
| October 31, 2013 | 0.739M |
| July 31, 2013 | 0.7729M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Exicure, Inc. | 0.174M |
| Century Therapeutics, Inc. | 16.98M |
| Absci Corp. | 22.62M |
| Celularity, Inc. | 1.92M |
| Cardio Diagnostics Holdings, Inc. | 0.1629M |